Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Devlin, Michael-John
1654  Ergebnisse:
Personensuche X
?
1

Disparity in the era of personalized medicine for epithelia..:

Devlin, Michael-John ; Miller, Rowan E.
Therapeutic Advances in Medical Oncology.  15 (2023)  - p. 175883592211480 , 2023
Link: https://doi.org/10.1177/..
 
?
2

The Tumor Microenvironment of Clear-Cell Ovarian Cancer:

Devlin, Michael-John ; Miller, Rowan ; Laforets, Florian...
Cancer Immunology Research.  10 (2022)  11 - p. 1326-1339 , 2022
Link: https://doi.org/10.1158/..
 
?
3

Immune Checkpoint Inhibition in Head and Neck Cancer:

Forster, Martin David ; Devlin, Michael-John
Frontiers in Oncology.  8 (2018)  - p. , 2018
Link: https://doi.org/10.3389/..
 
?
4

P3.02b-068 Outcomes of Patients with Advanced EGFR Mutation..:

Devlin, Michael-John ; Scullin, Paula ; Campbell, Lynn
Journal of Thoracic Oncology.  12 (2017)  1 - p. S1231 , 2017
Link: https://doi.org/10.1016/..
 
?
5

Real world study of sacituzumab govitecan in metastatic tri..:

Hanna, Daire ; Merrick, Sophie ; Ghose, Aruni...
British Journal of Cancer.  130 (2024)  12 - p. 1916-1920 , 2024
Link: https://doi.org/10.1038/..
 
?
6

The Tumor Microenvironment of Clear-Cell Ovarian Cancer:

Devlin, Michael-John ; Miller, Rowan ; Laforets, Florian...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627265/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
7

Pathological chemotherapy response score is prognostic in t..:

Cohen, Paul A ; Powell, Aime ; Böhm, Steffen...
https://mediatum.ub.tum.de/1542298.  , 2019
Link: https://mediatum.ub.tum...
 
?
8

Safety and efficacy of nivolumab monotherapy in recurrent o..:

Naumann, R. Wendel ; Hollebecque, Antoine ; Meyer, Tim...
http://eprints.gla.ac.uk/189910/1/189910.pdf.  , 2019
Link: http://eprints.gla.ac.uk..
 
?
9

Safety and Efficacy of Nivolumab Monotherapy in Recurrent o..:

Naumann, R Wendel ; Hollebecque, Antoine ; Meyer, Tim...
boreal:224190.  , 2019
Link: http://hdl.handle.net/20..
 
?
10

Safety and Efficacy of Nivolumab Monotherapy in Recurrent o..:

Naumann, R. Wendel ; Hollebecque, Antoine ; Meyer, Tim...
Journal of Clinical Oncology;37(31).  , 2019
Link: https://hdl.handle.net/1..
 
?
11

Safety and Efficacy of Nivolumab Monotherapy in Recurrent o..:

Naumann, R Wendel ; Hollebecque, Antoine ; Meyer, Tim...
boreal:224190.  , 2019
Link: http://hdl.handle.net/20..
 
?
12

Safety and Efficacy of Nivolumab Monotherapy in Recurrent o..:

Naumann, R. Wendel ; Hollebecque, Antoine ; Meyer, Tim...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823884/.  , 2019
Link: http://www.ncbi.nlm.nih...
 
?
13

Pathological chemotherapy response score is prognostic in t..:

Cohen, Paul A ; Powell, Aime ; Böhm, Steffen...
http://eprints.gla.ac.uk/217570/1/217570.pdf.  , 2019
Link: http://eprints.gla.ac.uk..
 
?
14

Immune Checkpoint Inhibition in Head and Neck Cancer:

Forster, Martin David ; Devlin, Michael-John
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6123367/.  , 2018
Link: http://www.ncbi.nlm.nih...
 
?
15

Tenecteplase versus alteplase for thrombolysis in patients ..:

Parsons, Mark W ; Yogendrakumar, Vignan ; Churilov, Leonid...
The Lancet Neurology.  , 2024
Link: https://doi.org/10.1016/..
 
1-15